Mimicking gut glial signals may extend life through lymphoid and epithelial protection
A brief local glial cell line-derived neurotrophic factor pulse with its required co-receptor may extend life through gut lymphoid cells and an interleukin-22-responsive lining. Benefit persisting after either required receptor response is disabled would reject the proposed minimal pair
Stage of verification
- Hypothesis published2026-10-05
- Indirect evidenceAssessed at 5 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Immune cell
Group 3 innate lymphoid cells
A population of innate lymphoid cells that can release interleukin-22
Where this hypothesis actsRET-positive cells in the intestinal mucosa exposed to a local GDNF pulse
Hypotheses on this target 1
Activation1
Clearance restoration
Reprogramming
Adoptive transfer
Elimination
Immunosuppression
Population balance
What is proposed
Activation
Stimulate interleukin-22 release
With whatProtein or peptide as the agent
HowDeliver a short, local pulse of GDNF with the required GFRα1 coreceptor available to activate RET
Possible result
Possible epithelial protection against repeated microbial injury and consequent lifespan extension
From the recordврождённых лимфоидных клеток третьего типа с рецептором RET
Specialised cell of an organ
Intestinal epithelial cells
Cells forming the intestinal epithelium that can mount a protective response to interleukin-22
Where this hypothesis actsInterleukin-22-responsive cells in intestinal mucosa subject to repeated microbial injury
Hypotheses on this target 1
Function restoration- Reprogramming
Transplantation- Elimination
Proliferation
What is proposed
Activate the epithelial protective programme
With whatProtein or peptide as the agent
HowUse interleukin-22 released by GDNF-stimulated lymphoid cells to trigger the epithelial receptor response
Possible result
Possible prevention of repeated microbial mucosal damage and consequent lifespan extension
From the recordкишечных эпителиальных клеток, отвечающих на интерлейкин-22
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Repeated damage to the intestinal lining could be one route through which gut health limits lifespan. The unexpected move is to replace a signal normally released by cells supporting the gut’s nerves with a brief local treatment, while requiring just two responding cell populations to carry its proposed benefit. This is a hypothesis generated by the pipeline, not a measured result.
- A brief local dose of the proposed signaling protein, with its helper protein available, would replace the signal normally supplied by gut glia.
- The replacement signal would activate the RET receptor on type 3 innate lymphoid cells.
- Those immune cells would release interleukin-22.
- Interleukin-22 would activate a protective response in the intestinal lining.
- That protection would persist between treatment cycles and reduce repeated damage caused by microorganisms.
- Less repeated damage would extend life.
A replacement alarm button still needs both someone to relay its message and a repair crew to act on it. Calling the repair crew directly could bypass the messenger, but could not replace the crew.
Where the picture breaks: Cells do not have such exclusive jobs, and the proposed signal can also act on the nervous system. The picture explains the predicted bypass but does not establish that only two cell populations are necessary or that activating them extends life.
- Master questionstep 01 of 04
Useful processes already performed by the body might be reproduced by new treatments that extend life.
Rests on: The stated goal is to propose new ways of reproducing beneficial bodily processes and explain why they might extend life.
Stated in the chain - Goal pillarstep 02 of 04
The intended output is a defined set of new treatments that imitate bodily processes for life extension.
Rests on: The master question explicitly requests new candidate treatments and the processes they would reproduce.
Stated in the chain - Gap questionstep 03 of 04
The search narrows to the tissues and cell populations each candidate must affect, with necessity judged by whether excluding each target removes the lifespan benefit.
Rests on: The goal requests a set of candidate treatments, but does not itself require this particular way of identifying their necessary targets.
AssumptionThe narrowing assumes that removing individual targets and observing loss of life extension is the relevant criterion for defining the required target set. The supplied goal does not establish that criterion.
- Hypothesisstep 04 of 04
A brief local treatment is proposed to replace a signal from enteric glia, cells that support nerves in the gut. The candidate is glial cell line-derived neurotrophic factor, a signaling protein, supplied with glial cell line-derived neurotrophic factor family receptor alpha 1, a helper protein needed for the proposed signal reception. The proposed responding pair consists of type 3 innate lymphoid cells, a class of immune cells, carrying the RET receptor, a signal-receiving protein named for 'rearranged during transfection,' and intestinal epithelial cells, the cells forming the gut lining. The immune cells would release interleukin-22, a signaling protein that the lining cells would receive to activate protection. The hypothesis counts these two populations as necessary because one supplies the messenger and the other carries out the protective response. It excludes glia from that responding set because the treatment would replace their signal. Preventing repeated microbial injury, meaning damage caused by microorganisms, is the proposed route to longer life; the required share of responding cells remains unknown.
Rests on: The preceding question calls for a target set whose members are individually necessary. The hypothesis supplies an explicit rationale for its proposed pair: a messenger-producing population followed by a population that performs the protective response.
Stated in the chain
What is carried, and what is not. Two screened sources speak to the proposed link between interleukin-22 and intestinal protection: S1, in Molecular Nutrition & Food Research in 2016, reported increased interleukin-22 alongside repair-related changes and better survival in mice with chemically induced acute intestinal inflammation, which does not establish that this messenger caused the benefit or extended natural lifespan; S4, in AMB Express in 2025, linked increased interleukin-22 with restored intestinal barrier function in zebrafish with diet-induced metabolic disorders, which does not establish the proposed signaling route or life extension. These sources provide partial support around one link in the six-link mechanism; none of the supplied screened sources establishes the replacement signal, the minimal responding pair, protection between cycles, or the complete sequence through longer life.S1S4
Where the reasoning is carried by something unstated · 1
- Gap question. The narrowing assumes that removing individual targets and observing loss of life extension is the relevant criterion for defining the required target set. The supplied goal does not establish that criterion.
How a result here could mislead · 3
- A benefit from the candidate signal could be credited entirely to the immune-cell relay even if effects on the nervous system also contribute. Conversely, losing benefit after disabling the immune-cell receptor would show that this response is necessary under those conditions, but would not by itself establish that the two named populations are sufficient. What closes it: The test must verify that receptor disabling is restricted to the intended cells and measure whether the treatment also changes nervous-system activity. A claim that only the proposed pair is required needs evidence separating their contribution from those other effects; the supplied testing outline does not specify that separation.
- Failure of direct interleukin-22 delivery to restore protection after the immune-cell receptor is disabled could be mistaken for failure of the relay model when the delivered messenger never produced the intended response in the lining. What closes it: The bypass comparison must verify delivery and the resulting response in lining cells. It must also verify that disabling the lining’s own response blocks that response as intended, so failed delivery and a broken causal prediction remain distinguishable.
- An early improvement in the lining could be read as evidence for durable protection or life extension, even if protection disappears between pulses or repeated stimulation produces harmful cell multiplication. The supplied hypothesis itself identifies abnormal cell multiplication as a concern with prolonged interleukin-22 activity. What closes it: The test must follow protection between treatment cycles, repeated injury, abnormal cell multiplication, and actual lifespan separately. Treatment timing and the criterion for persistent protection must be specified before testing; the supplied material provides neither numerical settings nor a defined lifespan measure.
What would make this wrong. The claimed necessity of the relay would fail if the candidate retained its lifespan benefit after verified, cell-specific disabling of either the immune-cell RET response or the lining’s interleukin-22 response. The proposed order would fail if direct interleukin-22 delivery, verified to activate the lining, could not bypass the immune-cell block. The final life-extension link would fail under the tested conditions if the intervention produced sustained protection and less repeated microbial injury without extending life. The supplied material does not define the treatment settings, necessary responding fraction, or operational lifespan measure needed to interpret such a negative result.
What it would change. If the full prediction held, imitating a protective gut signal would become a supported candidate approach to life extension, with its benefit requiring a defined immune-to-lining relay. Work on the master question would then need to distinguish the cells supplying the original bodily signal from the cells a replacement treatment actually requires, and to test whether direct treatment of the lining could achieve the same long-term effect with fewer required targets. Even a successful mouse test would leave human life extension unestablished, while results from jointly grown cells or short-term injury studies alone would leave life extension itself unestablished.
Sources read · 4
Purified rutin and rutin-rich asparagus attenuates disease severity and tissue damage following dextran sodium sulfate-induced colitis. · Molecular nutrition & food research · 2016
“In colitic mice, both ASP and RUT upregulated mediators of improved barrier integrity and enhanced mucosal injury repair (e.g. Muc1, IL-22, Rho-A, Rac1, and Reg3γ), increased the proportion of mouse survival, and improved disease activity index.”
Does not settle: Источник связывает повышение IL-22 с восстановлением слизистой и выживанием мышей при остром колите, вызванном DSS. Он не устанавливает роль GDNF, GFRα1, RET, энтеральной глии или врождённых лимфоидных клеток третьего типа, не подтверждает достаточность двух клеточных популяций, локальный импульсный режим, необходимую долю отвечающих клеток, защиту между повторными циклами повреждения или продление естественной продолжительности жизни.
Targeted deletion of keratin 8 in intestinal epithelial cells disrupts tissue integrity and predisposes to tumorigenesis in the colon. · Cellular and molecular life sciences : CMLS · 2021
“Colonic IL-22BP levels were strongly decreased, and p-STAT3 levels (Fig. F, G) and its STAT3 target gene S100A11 (Supplementary Fig. 6A) were increased in K8 flox/flox ; Villin-Cre epithelium, but not in K8 flox/− ; Villin-Cre, compared to K8 flox/flox controls.”
Does not settle: Источник не исследует GDNF, корецептор GFRα1, рецептор RET, энтеральную глию или врождённые лимфоидные клетки третьего типа. Он также не устанавливает, что двух клеточных популяций достаточно для защитного ответа, и не определяет параметры локального импульса, требуемую долю отвечающих клеток, защиту между циклами, предупреждение повторного микробного повреждения или влияние на продолжительность жизни.
The GS-nitroxide JP4-039 improves intestinal barrier and stem cell recovery in irradiated mice. · Scientific reports · 2018
“Given the highly dynamic and transient nature of IL-22 and Notch signaling during injury and regeneration and their key roles in development and health , , conditional or pharmacological manipulation is likely required to help better understand their significance and guide the development of new radiation mitigators.”
Does not settle: Источник не устанавливает участие GDNF, корецептора GFRα1, рецептора RET, энтеральной глии или врождённых лимфоидных клеток третьего типа. Он также не проверяет предложенный двухпопуляционный набор, локальный импульс миметика, необходимую долю отвечающих клеток, защиту между циклами повреждения или влияние на продолжительность жизни.
Akkermansia muciniphila alleviates metabolic disorders through gut microbiota-mediated tryptophan regulation. · AMB Express · 2025
“These metabolic shifts subsequently activate AhR , driving the upregulation of IL-22 and muc2 , Tjp-1α , claudin1 , and occludin , thereby restoring the barrier function, alleviating chronic inflammation and improving hepatic steatosis.”
Does not settle: Источник описывает рыбок данио с метаболическими нарушениями от высокожирового рациона и связывает интерлейкин-22 с восстановлением кишечного барьера. Он не устанавливает роль энтеральной глии, GDNF, GFRα1, RET или врождённых лимфоидных клеток третьего типа, не проверяет двухпопуляционный минимальный набор, локальный короткий импульс, необходимую долю отвечающих клеток, защиту между циклами повреждения или продление жизни.
The gap this hypothesis explains
Nothing is known here: the question has not been asked of this system.
Which tissues and cells must treatments mimicking bodily processes affect to extend life, and which treatments achieve this?
Original wording · exactly as the pipeline generated it
Какие ткани и клеточные популяции составляют причинно необходимый набор мишеней новых миметиков, какие физиологические процессы и вещества или воздействия ему соответствуют, если исключение каждой мишени устраняет продление жизни?
What this question is asking
The question concerns treatments that copy useful effects of the body's own processes and whether their effects on particular tissues and groups of cells are indispensable for extending life. It asks which processes must be copied, which substances or other interventions can copy them, and which tissues and cells must respond. The proposed test of necessity is that removing each target's contribution, one at a time, eliminates the treatment's life-extending effect. Success means longer remaining life than a comparison group under comparable starting conditions. The removal condition defines the evidence being sought; it is not presented as an experiment that has already succeeded.
- Mimetic
- A substance or intervention intended to reproduce an effect of another signal or bodily process. Reproducing one effect does not establish that it reproduces all effects, including any effect on lifespan.
- Tissue, cell population and target
- A tissue is an organized part of the body composed of cells; a cell population is a group of cells identified by shared features. Here, a target means a tissue or cell population whose response contributes to a treatment's effect.
- Necessary and sufficient
- A contribution is necessary when the benefit disappears without it under the tested conditions. A set is sufficient when producing its effects is enough to obtain the benefit; these are different claims.
- Remaining life
- The time lived after the chosen starting point. The pipeline asks for this time to be greater with treatment than in a comparison under comparable starting conditions, without supplying a measured increase.
- Insulin signaling
- The cellular response to the hormone insulin, a bodily chemical messenger. S5 concerns reducing this response in particular tissues, rather than identifying a complete set of indispensable targets.
- Caloric restriction
- An intervention that reduces dietary energy intake. The supplied S4 record reports its survival benefit but does not specify the restriction amount or schedule.
- Nuclear factor erythroid 2-related factor 2 (Nrf2)
- The named biological factor removed in S4. Its detailed molecular function is not established by the supplied material; the relevant finding is that the tested intervention still extended life without it.
- C57BL6/J mice
- The named laboratory mouse strain studied in S4. The supplied finding concerns males of this strain and does not establish the same result in all mice or humans.
- Brain-derived neurotrophic factor and 7,8-dihydroxyflavone
- Brain-derived neurotrophic factor is the biological signal that S2 describes 7,8-dihydroxyflavone as mimicking. The supplied passage reports an effect of this compound on developing fat cells, not an established survival benefit.
- Precursor cells and cell development
- Precursor cells are cells that can develop into a more specialized cell type. S2 concerns a laboratory cell population capable of becoming fat cells and reports reduced progression toward that state.
- Mitochondrial biogenesis
- The process of making and expanding the cell's mitochondria, structures involved in supplying usable energy. S6 states that drugs can manipulate this process but does not establish that doing so extends life.
- Gene activity and expression
- These terms concern cells using information in genes to produce biological products. S7 compares activity patterns associated with longevity; an association does not establish that changing the pattern causes longer life.
- Signaling pathway
- A connected sequence of events through which cells respond to a signal. S8 discusses pathways implicated both in life-extending interventions and in muscle growth and adaptation.
- Skeletal muscle
- The muscle tissue involved in moving the skeleton. S8 raises the question of how interventions associated with longer life relate to this tissue's growth and adaptation.
- Every target in a defined set is indispensable If a treatment extends life and removing each target's contribution separately abolishes that benefit, each target is necessary under those tested conditions. A treatment intended to reproduce that result would depend on preserving those contributions, although necessity alone would not show that acting on the targets is sufficient.
- Only some proposed targets are indispensable If removing certain targets abolishes the benefit while removing others leaves it intact, the proposed set includes contributions that are not individually required. Reproducing every associated cellular change would then overstate what the survival evidence establishes as necessary.
- No individual target is indispensable If the treatment still extends life after each target is removed separately, the proposed individual targets fail the question's necessity criterion. That result would leave unresolved whether contributions can substitute for one another or whether the relevant targets lie elsewhere.
- The treatment does not extend life If copying the selected processes does not increase remaining life under comparable conditions, there is no demonstrated survival benefit for target removal to explain. The treatment could still change cells or tissues, but those changes would not establish the requested life extension.
Changing a process in a cell does not by itself establish that the change makes an organism live longer. A treatment could produce that cellular change while its effect on survival depends on another tissue, or while survival remains unchanged. Even when changing one tissue extends life, that does not establish that the tissue is indispensable to a different treatment's benefit. Confusing these steps would turn evidence of a cellular effect into an unsupported claim about a life-extending treatment and its required targets.
S-узлы описывают отдельные клеточные зависимости преимущественно уровня RL-1; состав достаточных наборов миметиков и мишеней отсутствует.
Определённый состав миметиков и необходимых мишеней, обеспечивающих отношение оставшейся продолжительности жизни выше единицы при сопоставимых исходных условиях.
Неизвестно, какие сочетания мишеней превращают воспроизведение отдельных физиологических звеньев в продление жизни и какие вещества способны воспроизвести это сочетание.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Минимальный набор для миметика защитного ответа слизистой состоит из двух популяций: врождённых лимфоидных клеток третьего типа с рецептором RET и кишечных эпителиальных клеток, отвечающих на интерлейкин-22. Предлагаемый миметик представляет собой локальный короткий импульс нейротрофического фактора GDNF с обеспечением необходимого корецептора GFRα1. Он воспроизводит физиологическую секрецию энтеральной глии, запускает выделение интерлейкина-22 лимфоидными клетками и последующую защитную программу эпителия. Глия служит прототипным источником сигнала, который заменяет препарат, поэтому в необходимый набор клеточных ответов она не входит. Размер набора равен двум популяциям. Требуемая доля отвечающих клеток неизвестна; проверяется минимальный охват слизистой, при котором защита сохраняется между циклами. Одного эпителиального или одного лимфоидного ответа недостаточно: первый требует поддерживающего посредника, второй требует ткани-исполнителя. Предполагаемая польза для SPV_2 возникает через предупреждение повторного микробного повреждения слизистой.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
Миметик продлевает жизнь при сохранённой паре «RET-положительная лимфоидная клетка, эпителий с ответом на интерлейкин-22», даже если дополнительное привлечение секреторных предшественников и перестройка матрикса удерживаются на исходном уровне. Выключение RET исключительно в этих лимфоидных клетках или рецепторного ответа на интерлейкин-22 в эпителии устраняет пользу. Прямое введение интерлейкина-22 должно обходить первое выключение, но не второе. Если прямой эпителиальный миметик даёт тот же долговременный эффект, двухпопуляционный набор оказывается больше необходимого для этого альтернативного препарата.
Would tell it apart from at least one rival. The text predicts lifespan extension under specified constraints, loss of benefit after either targeted disruption, and rescue of only the first disruption by direct interleukin-22 administration. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Исходную цепочку можно исследовать в совместных культурах и мышиных моделях с клеточно-избирательным выключением рецепторов. Сложность кандидата состоит в ограничении действия GDNF выбранными лимфоидными клетками: он также действует на нервную систему. Продолжительное усиление интерлейкина-22 может поддерживать патологическую пролиферацию.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
Миметик продлевает жизнь при сохранённой паре «RET-положительная лимфоидная клетка, эпителий с ответом на интерлейкин-22», даже если дополнительное привлечение секреторных предшественников и перестройка матрикса удерживаются на исходном уровне. Выключение RET исключительно в этих лимфоидных клетках или рецепторного ответа на интерлейкин-22 в эпителии устраняет пользу. Прямое введение интерлейкина-22 должно обходить первое выключение, но не второе. Если прямой эпителиальный миметик даёт тот же долговременный эффект, двухпопуляционный набор оказывается больше необходимого для этого альтернативного препарата.
- Rival 01 of 03What would separate them
Genome doubling in mature gut cells may repair surface defects and extend remaining life predicts: При сохранённом базовом обновлении эпителия миметик увеличивает оставшуюся продолжительность жизни даже тогда, когда дополнительное деление стволовых клеток удерживается на исходном уровне. Увеличенные зрелые клетки сохраняют свою идентичность и закрывают дефекты; образования новых стволовых клеток из них не происходит. Избирательное выключение эндоредупликации в зрелой популяции устраняет пользу, а её восстановление возвращает эффект. Если для выигрыша обязательно усиленное образование новых клеток, преимущество получают наборы 02 или 04.
- Rival 02 of 03What would separate them
Reserve cells may extend life by restoring intestinal crypts after renewal cells are lost predicts: При одинаковом среднем числе новых эпителиальных клеток продление жизни возникает только при сохранённой способности Dll1-положительных предшественников восстанавливать крипты. Отключение этой способности увеличивает частоту редких необратимых потерь крипт и устраняет выигрыш выживаемости, хотя средний пролиферативный ответ остаётся прежним. Вероятность восстановления меняется с числом доступных резервных клеток по предсказанию модели. Сохранение пользы при выключенном резерве поддержит иной минимальный набор.
- Rival 03 of 03What would separate them
Restoring support flexibility may let intestinal progenitors complete repair and extend life predicts: Выигрыш оставшейся продолжительности жизни сопровождается восстановлением механических свойств перикриптальной опоры и исчезает, если матрикс экспериментально удерживается в исходном жёстком состоянии при сохранённом химическом воздействии. Обходное восстановление податливости опоры возвращает пользу. Избирательное выключение дополнительного механического ответа эпителиальных предшественников также устраняет эффект. При этой гипотезе усиление лимфоидной секреции или доступности резервных предшественников само по себе оставляет хронические дефекты при прежней механике матрикса.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.